Corrigendum to “Prophylactic Effects of Sulforaphane on Depression-Like Behavior and Dendritic Changes in Mice After Inflammation” Journal of Nutritional Biochemistry 39 (2017) 134–144 (Journal of Nutritional Biochemistry (2017) 39 (134–144), (S0955286316301152), (10.1016/j.jnutbio.2016.10.004));Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation

Journal of Nutritional Biochemistry

Volumn 39, Issue , 2017, Pages 134-144

  Zhang, Ji chun ^a   Yao, Wei ^a   Dong, Chao ^a   Yang, Chun ^a   Ren, Qian ^a   Ma, Min ^a   Han, Mei ^a   Wu, Jin ^a   Ushida, Yusuke ^b   Suganuma, Hiroyuki ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b KAGOME CO   (Japan)

Author keywords

Brain derived neurotrophic factor; Depression; Inflammation; Nrf2; Prevention; Sulforaphane; Synaptogenesis

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR 1; BRAIN DERIVED NEUROTROPHIC FACTOR; CD11B ANTIGEN; GLUCORAPHANIN; GLUCOSINOLATE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; POSTSYNAPTIC DENSITY PROTEIN 95; SULFORAPHANE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; DISKS LARGE HOMOLOG 4; DLG4 PROTEIN, MOUSE; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; IMIDOESTER; ISOTHIOCYANIC ACID DERIVATIVE; SULFORAFAN;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL DENSITY; CONTROLLED STUDY; DENDRITIC SPINE; DENTATE GYRUS; DEPRESSION; DIETARY INTAKE; FORCED SWIM TEST; GOLGI STAIN; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; IMMOBILITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; JUVENILE ANIMAL; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PROPHYLAXIS; PROTEIN BLOOD LEVEL; TAIL SUSPENSION TEST; WESTERN BLOTTING; ANIMAL; ANIMAL BEHAVIOR; BLOOD; BRASSICA; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; BRASSICA; DEPRESSION; DISEASE MODELS, ANIMAL; DISKS LARGE HOMOLOG 4 PROTEIN; GLUCOSINOLATES; IMIDOESTERS; INFLAMMATION; INTERLEUKIN-10; ISOTHIOCYANATES; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, AMPA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84994339109     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2020.108550     Document Type: Erratum

References (61)

1. [1] Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9 (2008), 46–47.
2. [2] Hashimoto, K., Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61 (2009), 105–123.
3. [3] Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65 (2009), 732–741.
4. [4] Raison, C.L., Lowry, C.A., Rook, G.A., Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry 67 (2010), 1211–1224.
5. [5] Hashimoto, K., Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci 16 (2015), 7796–7801.
6. [6] Zhang, J.C., Yao, W., Hashimoto, K., Brain-derived neurotrophic factor (BDNF) – TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol 14 (2016), 721–731.
7. [7] Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 67 (2010), 446–457.
8. [8] Hiles, S.A., Baker, A.L., de Malmanche, T., Attia, J., A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun 26 (2012), 1180–1188.
9. [9] Shelton, R.C., Claiborne, J., Sidoryk-Wegrzynowicz, M., Reddy, R., Aschner, M., Lewis, D.A., et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 16 (2011), 751–762.
10. [10] O'Connor, J.C., Lawson, M.A., André, C., Moreau, M., Lestage, J., Castanon, N., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14 (2009), 511–522.
11. [11] Ohgi, Y., Futamura, T., Kikuchi, T., Hashimoto, K., Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 103 (2013), 856–859.
12. [12] Yao, W., Zhang, J.C., Dong, C., Zhuang, C., Hirota, S., Inanaga, K., et al. Effects of amycenone on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 136 (2015), 7–12.
13. [13] Dong, C., Zhang, J.C., Yao, W., Ren, Q., Yang, C., Ma, M., et al. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 144 (2016), 7–12.
14. [14] Bazinet, R.P., Layé, S., Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 15 (2014), 771–785.
15. [15] El-Behadli, A.F., Sharp, C., Hughes, S.O., Obasi, E.M., Nicklas, T.A., Maternal depression, stress and feeding styles: towards a framework for theory and research in child obesity. Br J Nutr 113 (2015), S55–S71.
16. [16] Mello, A.H., Gassenferth, A., Souza, L.R., Fortunato, J.J., Rezin, G.T., ω-3 and major depression: a review. Acta Neuropsychiatr 26 (2014), 178–185.
17. [17] Mukakami, K., Sasaki, S., Dietary intake and depressive symptoms: a systemic review of observational studies. Mol Nutr Food Res 54 (2010), 471–488.
18. [18] Opie, R.S., O'Neil, A., Itsiopoulos, C., Jacka, F.N., The impact of whole-of-diet interventions on depression and anxiety: a systematic review of randomised controlled trials. Public Health Nutr 18 (2015), 2074–2093.
19. [19] Lai, J.S., Hiles, S., Bisquera, A., Hure, A.J., McEvoy, M., Attia, J., A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. Am J Clin Nutr 99 (2014), 181–197.
20. [20] Zhang, Y., Li, J., Tang, L., Cancer-preventive isothiocyanates: dichotomous modulators of oxidative stress. Free Radic Biol Med 38 (2005), 70–77.
21. [21] Juge, N., Mithen, R.F., Traka, M., Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 64 (2007), 1105–1127.
22. [22] Zhang, Y., Talalay, P., Cho, C.G., Posner, G.H., A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci 89 (1992), 2399–2403.
23. [23] Fahey, J.W., Zhang, Y., Talalay, P., Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci 94 (1997), 10367–10372.
24. [24] Kensler, T.W., Egner, P.A., Agyeman, A.S., Visvanathan, K., Groopman, J.D., Chen, J.G., et al. Keap1-Nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem 329 (2013), 163–177.
25. [25] Kwak, M.K., Kensler, T.W., Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244 (2010), 66–76.
26. [26] Itoh, K., Tong, K.I., Yamamoto, M., Molecular mechanism activating Nrf2–Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med 36 (2004), 1208–1213.
27. [27] Kang, K.W., Lee, S.J., Kim, S.G., Molecular mechanism of nrf2 activation by oxidative stress. Antioxid Redox Signal 7 (2005), 1664–1673.
28. [28] Cheung, K.L., Kong, A.N., Molecular targets of dietary phenylethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPSJ 12 (2010), 87–97.
29. [29] Chen, H., Wu, J., Zhang, J., Fujita, Y., Ishima, T., Iyo, M., et al. Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine. Psychopharmacology (Berl) 222 (2011), 37–45.
30. [30] Shirai, Y., Fujita, Y., Hashimoto, K., Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration. Clin Psychopharmacol Neurosci 10 (2012), 94–98.
31. [31] Shirai, Y., Fujita, Y., Hashimoto, R., Ohi, K., Yamamori, H., Yasuda, Y., et al. Dietary intake of sulforaphane-rich broccoli sprout extracts during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood. PLoS One, 10, 2015, e0127244.
32. [32] Hahsimoto, K., Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets 18 (2014), 1049–1063.
33. [33] Hashimoto, K., Shimizu, E., Iyo, M., Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45 (2004), 104–114.
34. [34] Duman, R.S., Monteggia, L.M., Neurotrophic model for stress-related mood disorders. Biol Psychiatry 59 (2006), 1116–1127.
35. [35] Nestler, E.J., Carlezon, W.A. Jr., The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59 (2006), 1151–1159.
36. [36] Martinowich, K., Manji, H., Lu, B., New insights into BDNF function in depression and anxiety. Nat Neurosci 10 (2007), 1089–1093.
37. [37] Hashimoto, K., Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64 (2010), 341–357.
38. [38] Hashimoto, K., Sigma-1 receptor chaperone and brainderived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 100 (2013), 15–29.
39. [39] Castrén, E., Neurotrophins and psychiatric disorders. Handb Exp Pharmacol 220 (2014), 461–479.
40. [40] McEwen, B.S., Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87 (2007), 873–904.
41. [41] Duman, R.S., Aghajanian, G.K., Synaptic dysfunction in depression: potential therapeutic targets. Science 338 (2012), 68–72.
42. [42] Ohgi, Y., Futamura, T., Hashimoto, K., Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med 15 (2015), 206–221.
43. [43] Yang, C., Shirayama, Y., Zhang, J.C., Ren, Q., Yao, W., Ma, M., et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry, 5, 2015, e632.
44. [44] Franklin, K.B.J., Paxinos, G., The mouse brain in the stereotaxic coordinates. 1997, Academic, San Diego.
45. [45] Zhang, J.C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., et al. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol, 18, 2015, pyu077.
46. [46] Zhang, J.C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., et al. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 232 (2015), 4325–4335.
47. [47] Ren, Q., Ma, M., Yang, C., Zhang, J.C., Yao, W., Hashimoto, K., BDNF–TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms. Transl Psychiatry, 5, 2015, e666.
48. [48] Ma, M., Ren, Q., Zhang, J.C., Hashimoto, K., Effects of brilliant blue G on serum tumor necrosis factor-α levels and depression-like behavior in mice after lipopolysaccharide administration. Clin Psychopharmacol Neurosci 12 (2014), 31–36.
49. [49] Shirayama, Y., Yang, C., Zhang, J.C., Ren, Q., Yao, W., Hashimoto, K., Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur Neuropsychopharmacol 25 (2015), 2449–2458.
50. [50] Fahey, J.W., Talalay, P., Kensler, T.W., Notes from the field: “green” chemoprevention as frugal medicine. Cancer Prev Res (Phila) 5 (2012), 179–188.
51. [51] Tortorella, S.M., Royce, S.G., Licciardi, P.V., Karagiannis, T., Dietary sulforaphane in cancer chemoprevention: the role of epigenetic regulation and HDAC inhibition. Antioxid Redox Signal 22 (2015), 1382–1424.
52. [52] Benedict, A.L., Mountney, A., Hurtado, A., Bryan, K.E., Schnaar, R.L., Dinkova-Kostova, A.T., et al. Neuroprotective effects of sulforaphane after contusive spinal cord injury. J Neurotrauma 29 (2012), 2576–2586.
53. [53] Singh, K., Connors, S.L., Macklin, E.A., Smith, K.D., Fahey, J.W., Talalay, P., et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci 111 (2014), 15550–15555.
54. [54] Shiina, A., Kanahara, N., Sasaki, T., Oda, Y., Hashimoto, T., Hasegawa, T., et al. An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia. Clin Psychopharmacol Neurosci 13 (2015), 62–67.
55. [55] Innamorato, N.G., Rojo, A.I., García-Yagüe, A.J., Yamamoto, M., de Ceballos, M.L., Cuadrado, A., The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181:1 (2008), 680–689.
56. [56] Qin, L., Wu, X., Block, M.L., Liu, Y., Breese, G.R., Hong, J.S., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55:5 (2007), 453–462.
57. [57] Sun, C.C., Li, S.J., Yang, C.L., Xue, R.L., Xi, Y.Y., Wang, L., et al. Sulforaphane attenuates muscle inflammation in dystrophin-deficient mdx mice via NF-E2-related factor 2 (Nrf2)-mediated inhibition of NF-κB signaling pathway. J Biol Chem 290:29 (2015), 17784–17795.
58. [58] Yao, W., Zhang, J.C., Ishima, T., Dong, C., Yang, C., Ren, Q., et al. Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice. Sci Rep, 6, 2016, 30659.
59. [59] Paus, T., Keshavan, M., Giedd, J.N., Why do many psychiatric disorders emerge during adolescence?. Nat Rev Neurosci 9 (2008), 947–957.
60. [60] O'Connor, R.M., Cryan, J.F., Adolescent brain vulnerability and psychopathology through the generations: role of diet and dopamine. Biol Psychiatry 75 (2014), 4–6.
61. [61] Sim, K., Lau, W.K., Sim, J., Sum, M.Y., Baldessarini, R.J., Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol, 18, 2015, pyv076.